This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
Number of primary studies included
Twelve primary studies were included in the analysis.
Methods of combining primary studies
The data from multiple studies were pooled using a fixed effects method to derive individual probability estimates for the model. The authors reported that each probability was converted to a constant annual rate, and solved for the monthly transition probability. The method used for the conversion was not reported. Normal distribution or exact binomial confidence limit tables were used to estimate 95% confidence intervals, depending on the sample size.
Investigation of differences between primary studies
The authors did not state if the differences between primary studies were investigated.
Results of the review
The following pooled monthly transition probabilities were used as inputs to the model. Fistula improves after infliximab = 0.70 (95% CI: 0.63 -0.77).
Fistula recurs after infliximab = 0.18 (95% CI: 0.10 -0.26).
Abscess occurs after infliximab = 0.06 (95% CI = 0.01 -0.21).
Abscess recurs after incision and drainage = 0.03 (95% CI: 0.01 -0.08).
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Fistula improves after 6-mercaptopurine and metronidazole = 0.48 (95% CI: 0.27 -0.69).
Fistula recurs after 6-mercaptopurine and metronidazole is stopped = 0.14 (95% CI: 0.05 -0.33).
Fistula recurs while taking 6-mercaptopurine and metronidazole = 0.01 (95% CI: 0.00 -0.10).
Pancreatitis occurs = 0.03 (95% CI: 0.01 -0.08).
Paresthesias occurs = 0.10 (95% CI: 0.04 -0.16).
Methods used to derive estimates of effectiveness
The expert opinion of gastroenterologists and colorectal surgeons, supported by a literature review, was used to develop the structure of the model.
Estimates of effectiveness and key assumptions
The authors reported that clinically relevant endpoints are a subject of debate. The assumed endpoint in this analysis was 'fistula improvement' defined as complete closure or symptomatic improvement.
In the comparator strategy, patients who did not respond to treatment during the 12 month time-horizon were transitioned to persistent fistula and remained there until the model was complete.
The authors reported that the probability of improvement after episodic reinfusion with infliximab is unknown. For the base case for intervention II it was assumed that, for patients who responded to initial infusion, the mean probability of improvement after episodic reinfusion was equivalent to the mean probability of improvement after initial infusion.
For intervention III, the base case assumed that infliximab was equally effective for first-line and second-line infliximab therapy.
The authors reported there were no long term data on the rate of relapse after treatment with infliximab and the literature review indicated that 75% of patients lost their initial response within the first 3.75 months. In the base case it was assumed that the monthly probability that a fistula recurs after infliximab treatment was 18% per month for months 2-4, then decreased by 3% per month to the end of the 1-year time frame.
Based on the literature, the benefits from the initial infusion with infliximab were assumed to occur within the first month after infusion.
The effects of 6-mercaptopurine and metronidazole were assumed not to be additive or synergistic and metronidazole was assumed to provide the initial therapeutic benefit whilst 6-mercaptopurine would help maintain this benefit.
All health states were assumed to last for at least one cycle (1-month) with the exception of pancreatitis, which was assumed to last one week.
Neutropenia was not included as a side effect from 6-mercaptopurine and metronidazole in the model because it was assumed to have minimal effects on costs and patient preference weights.
Measure of benefits used in the economic analysis
The measure of benefit used in the economic analysis was the Quality-Adjusted Life Year (QALY). Standard gamble techniques were used to elicit the preference weights (utility), for the 11 health states used in the model, from two samples of respondents: a sample of 32 patients (17 with fistulae and 15 with no fistulae) with Crohn's disease and a sample of 20 healthy individuals.
Separate analyses were conducted using the utilities from these two samples. Differences in utilities between the two samples and between patients with Crohn's disease, with and without a history of fistulae, were assessed using a t-test.
The estimation of unit costs was based on the University of Virginia (UVA) hospital cost-charge ratios. Charge data were obtained from the UVA Clinical Data Repository, an administrative database containing hospital and physician billing data for all inpatient and outpatient admissions to UVA between 1 July 1993 and 31 December 1999. Average total costs were reported in 1999 US dollars. The authors did not report the method used to adjust for inflation over the 6 year period covered by the UVA database. The authors excluded direct costs to other care providers on the basis that they would be consistent between the alternative interventions.
For infliximab strategies, the following costs for each health state were used: fistula = $8,000; reinfusion = $2,609; abscess = $1,985; persistent fistula = $99; persistent fistula and previous abscess = $99.
For 6-mercaptopurine and metronidazole strategies, the following total costs were reported: fistula = $992; paresthesias = $394; pancreatitis = $2,027; improved fistula = $168; persistent fistula = $267; fistula persisted when off medications = $99.
Costs were discounted at an annual rate of 3%.
Statistical analysis of costs
No statistical analysis of costs was reported.
Indirect Costs
Indirect costs were not included in the analysis. The authors reported that, although the indirect costs associated with the condition are recognised as significant burdens among patients with Crohn's disease, such costs are difficult to quantify monetarily, and they were assumed to be reasonably consistent among the three interventions.
Currency

US dollars ($). No currency conversions were reported.
Sensitivity analysis
One-way sensitivity analyses were performed on all cost, probability, and utility estimates in the model, as well as the time course for loss of response after infliximab. Each probability variable was tested over its 95% confidence interval. Cost data were varied by 25% and the effectiveness of infliximab was varied between 0% and 100%. A threshold analysis was performed on the costs of a single dose of infliximab. Tornado diagrams were used to identify influential variables and additional sensitivity analyses on incremental cost utility ratios were conducted.
Estimated benefits used in the economic analysis
The QALYs obtained from the preference weights (utilities) from the patients with Crohn's disease were:
6-mercaptopurine and metronidazole = 0.76 QALYs;
3 infliximab infusions plus 6-mercaptopurine and metronidazole as second line = 0.78 QALYs;
infliximab with episodic reinfusion = 0.78 QALYs;
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The QALYs obtained from the preference weights (utilities) from the healthy individuals were:
6-mercaptopurine and metronidazole = 0.82 QALYs;
3 infliximab infusions plus 6-mercaptopurine and metronidazole as second line = 0.84 QALYs;
infliximab with episodic reinfusion = 0.83 QALYs;
6-mercaptopurine and metronidazole plus infliximab as second line = 0.84 QALYs.
Cost results
The total cost for 6-mercaptopurine and metronidazole was $2,894.
The total cost for 3 infliximab infusions plus 6-mercaptopurine and metronidazole as second line was $10,003.
The total cost for infliximab with episodic reinfusion was $10,112.
The total cost for 6-mercaptopurine and metronidazole plus infliximab as second line was $6,664.
Synthesis of costs and benefits
Using preference weights from patients with Crohn's disease, the incremental cost-utility ratios for the base case were:
$355,450 per QALY for 3 infliximab infusions plus 6-mercaptopurine and metronidazole as second line versus 6-mercaptopurine and metronidazole (comparator); $360,900 per QALY for infliximab with episodic reinfusion versus 6-mercaptopurine and metronidazole (comparator); $377,000 per QALY for 6-mercaptopurine and metronidazole plus infliximab as second line versus 6-mercaptopurine and metronidazole (comparator).
Using preference weights from healthy individuals, the incremental cost-utility ratios for the base case were:
$355,450 per QALY for 3 infliximab infusions plus 6-mercaptopurine and metronidazole as second line versus 6-mercaptopurine and metronidazole (comparator); $721,800 per QALY for infliximab with episodic reinfusion versus 6-mercaptopurine and metronidazole (comparator); $188,500 per QALY for 6-mercaptopurine and metronidazole plus infliximab as second line versus 6-mercaptopurine and metronidazole (comparator).
The most influential variable in the model was the unit cost of infliximab. The threshold analysis on the cost of a single dose of infliximab for a 70kg person found that reducing the cost of infliximab from its 1999 wholesale price of $2,030 to $203 would reduce the incremental cost-utility ratio of infliximab with episodic reinfusion compared to 6-mercaptopurine and metronidazole to $36,050 per QALY.
The one-way sensitivity analysis showed that the model was also sensitive to the estimates for the monthly probability of paresthesias, utility for improved and persistent fistula health states, the monthly probability that a fistula improves after infliximab or 6-mercaptopurine metronidazole therapy.
A two-way sensitivity analysis that simultaneously varied the utility weights for persistent fistula after infliximab and after 6-mercaptopurine metronidazole treatments and for improved fistula after these therapies showed that incremental cost-utility ratios below $150,000 per QALY occur only if patients value an improved fistula after infliximab therapy much higher than after 6-mercaptopurine and metronidazole therapy.
